Most Popular News Stories on OBR Daily
The ten most read articles fromOBR Daily in the past month, updated continually:
(StreetInsider) Jan 2, 2018 - Five Prime Therapeutics, Inc. today announced that on December 27, 2017, the company initiated dosing in the Phase 1 portion of the FIGHT Phase 1/3 clinical trial (NCT03343301) of FPA144, an isoform-selective anti-FGF receptor 2b antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric or gastroesophageal cancer.
(StreetInsider) Jan 8, 2018 - Companies will partner on preclinical activities and early-stage studies for program targeting Wnt signaling pathway; StemSynergy’s novel approach has the potential to address a major pathway deregulated in many cancers.
(Beth Israel Deaconess Medical Center) Jan 11, 2018 - Analyzing individuals’ genotypes and immunotypes could yield customized treatments.
(StreetInsider) Jan 8, 2018 - GE Healthcare has entered into a strategic, long-term partnership with Roche to jointly develop and co-market digital clinical decision support solutions.
(U.S. News & World Report/Associated Press) Dec 28, 2017 - A psychiatrist who pioneered the field of psycho-oncology to help patients cope with the emotional impact of cancer has died. Dr. Jimmie Coker Holland was 89.
(StreetInsider) Jan 8, 2018 - Aptevo Therapeutics Inc. today announced that it has commenced patient dosing in a Phase 2 clinical evaluation of otlertuzumab in a new indication – peripheral T-cell lymphoma (PTCL). Otlertuzumab is a monospecific antibody targeting CD37 that was built on Aptevo’s ADAPTIR™ modular protein therapeutic platform.
(Forbes) Dec 31, 2017 - Few doctors, even oncologists who subspecialize, can keep up with developments in the field.
(MD Anderson) Jan 4, 2018 - Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center.
(Journal Of Clinical Pathways) Jan 9, 2018 - A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), published in BMC Cancer (online January 3, 2018; doi:10.1186/s12885-017-3720-8).
(Merck) Jan 8, 2018 - Merck, known as MSD outside the United States and Canada, and The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for surgically resected high-risk melanoma, met the primary endpoint of recurrence-free survival (RFS).